Evidence map›Paper›PMID 42329435›Full record

ReviewArchives of microbiology2026

Review: natural compounds as PCSK9 inhibitors for antiviral therapy.

Radhwan Abdul Kareem, Hayder Naji Sameer, Zainab H Athab, Mohaned Adil, Ahmed Yaseen, Omer Qutaiba B Allela

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Radhwan Abdul KareemAhl Al Bayt University, Kerbala, Iraq.
Hayder Naji SameerCollage of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, Iraq.
Zainab H AthabDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Mohaned AdilPharmacy college, Al-Farahidi University, Baghdad, Iraq.
Ahmed YaseenGilgamesh Ahliya University, Baghdad, Iraq.
Omer Qutaiba B AllelaCollege of Pharmacy, Alnoor University, Nineveh, Iraq. omerallela@alnoor.edu.iq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

From the perspective of both the host cell and the virus, cholesterol (CHO) plays a critical role during viral infection. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases the risk of cardiovascular disease by regulating plasma levels of lipoprotein(a), triglyceride-rich lipoproteins, and low-density lipoprotein cholesterol (LDL-C), and by promoting the degradation of the LDL receptor (LDLR). Emerging evidence implicates PCSK9 in the pathophysiology of several viral diseases, including human immunodeficiency virus (HIV), SARS-CoV-2, dengue virus (DENV), and hepatitis viruses. Two monoclonal antibody PCSK9 inhibitors (PCSK9i), evolocumab (Repatha

Indexed as

Antiviral AgentsBiological ProductsPCSK9 InhibitorsVirus DiseasesAnimalsAntibodies, Monoclonal, HumanizedHumansProprotein Convertase 9SARS-CoV-2alirocumabAntibodies, Monoclonal, HumanizedAntiviral AgentsBiological ProductsevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Lipid-lowering drugsNatural compoundsPCSK9Viral infection

Identifiers

PMID42329435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.